NCI Opens Up Phase III Trials

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 7
Volume 11
Issue 7

BETHESDA, Maryland-Oncologists nationwide now have access to National Cancer Institute (NCI) clinical trials under a new policy intended to encourage a wider participation in phase III studies. The new policy makes it easier for oncologists to become credentialed as investigators and to enroll their patients in the advanced studies through NCI’s Cancer Trials Support Unit (CTSU). Previously, access to NCI’s clinical trials was limited to members of NCI’s cooperative groups.

BETHESDA, Maryland—Oncologists nationwide now have access to National Cancer Institute (NCI) clinical trials under a new policy intended to encourage a wider participation in phase III studies. The new policy makes it easier for oncologists to become credentialed as investigators and to enroll their patients in the advanced studies through NCI’s Cancer Trials Support Unit (CTSU). Previously, access to NCI’s clinical trials was limited to members of NCI’s cooperative groups.

Oncologists can use the web-based CTSU to download protocols, case report forms, and other documents.

Interested physicians can enter the program through a two-phase application and credentialing process, which will include a site visit to ensure an oncologist’s capability to meet regulatory requirements and collect research data successfully. Information on the project is available online at www.ctsu.org, or by calling 1-888-823-5923.

Recent Videos
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content